What are the risks of injecting grey -market peptides
The Lancet, 368 (9548), 1696-1705
App Tracking: The WeightWatchers app gives you a full suite of tracking tools
"This portfolio of publications, derived from three major trials, significantly advances our understanding of the wide-ranging benefits of GLP-1 agonists, while also highlighting key questions that remain," said JACC Editor-in-Chief Harlan Krumholz, MD, SM, FACC
Weekly injections remain foundational, but daily oral therapy adds another entry point into care, particularly for patients hesitant about needles or seeking a treatment that fits more seamlessly into a morning routine